Access to a variety of PrEP methods allows women to choose what best suits them, depending on their context and where they are in their reproductive lifespan.
At the Red Ribbon Gala, the government says it supports the Malaysian AIDS Foundation's work with the Human Resources Ministry to amend the Employment Act and the Industrial Relations Act to protect people living with HIV from workplace discrimination.
Our approach to the HIV/ AIDS crisis should prioritise public health outcomes rather than causing the persecution and further marginalisation of communities already on the fringes of society.
Malaysia's DCA has approved Apretude (cabotegravir) for high-risk groups after an Asean joint assessment, the first and only treatment by injection for HIV pre-exposure prevention. Cabotegravir only has to be taken every 2 months, unlike daily PrEP pills.
Infectious disease expert Prof Dr Christopher Lee says accessibility and affordability of HIV treatments have improved, yet societal discrimination poses barriers to care.